Biosimilar adalimumab: Additional Phase III data

Data from 508 patients with moderate to severe RA despite methotrexate therapy in a double-blind, European Phase III trial showed that 40 mg subcutaneous SB5 every other week led to an ACR20 response rate at week 52

Read the full 370 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE